BACKGROUND: Acute coronary syndrome is a leading cause of death in developed countries. Follistatin-like 1 (FSTL1) is a myocyte-derived secreted protein that is upregulated in the heart in response to ischemic insult. Here, we investigated the therapeutic impact of FSTL1 on acute cardiac injury in small and large preclinical animal models of ischemia/reperfusion and dissected its molecular mechanism. METHODS AND RESULTS: Administration of human FSTL1 protein significantly attenuated myocardial infarct size in a mouse or pig model of ischemia/reperfusion, which was associated with a reduction of apoptosis and inflammatory responses in the ischemic heart. Administration of FSTL1 enhanced the phosphorylation of AMP-activated protein kinase in the ischemia/reperfusion-injured heart. In cultured cardiac myocytes, FSTL1 suppressed apoptosis in response to hypoxia/reoxygenation and lipopolysaccharide-stimulated expression of proinflammatory genes through its ability to activate AMP-activated protein kinase. Ischemia/reperfusion led to enhancement of bone morphogenetic protein-4 expression and Smad1/5/8 phosphorylation in the heart, and FSTL1 suppressed the increased phosphorylation of Smad1/5/8 in ischemic myocardium. Treating cardiac myocytes with FSTL1 abolished the bone morphogenetic protein-4-stimulated increase in apoptosis, Smad1/5/8 phosphorylation, and proinflammatory gene expression. In cultured macrophages, FSTL1 diminished lipopolysaccharide-stimulated expression of proinflammatory genes via activation of AMP-activated protein kinase and abolished bone morphogenetic protein-4-dependent induction of proinflammatory mediators. CONCLUSIONS: Our data indicate that FSTL1 can prevent myocardial ischemia/reperfusion injury by inhibiting apoptosis and inflammatory response through modulation of AMP-activated protein kinase- and bone morphogenetic protein-4-dependent mechanisms, suggesting that FSTL1 could represent a novel therapeutic target for post-myocardial infarction, acute coronary syndrome.
BACKGROUND:Acute coronary syndrome is a leading cause of death in developed countries. Follistatin-like 1 (FSTL1) is a myocyte-derived secreted protein that is upregulated in the heart in response to ischemic insult. Here, we investigated the therapeutic impact of FSTL1 on acute cardiac injury in small and large preclinical animal models of ischemia/reperfusion and dissected its molecular mechanism. METHODS AND RESULTS: Administration of humanFSTL1 protein significantly attenuated myocardial infarct size in a mouse or pig model of ischemia/reperfusion, which was associated with a reduction of apoptosis and inflammatory responses in the ischemic heart. Administration of FSTL1 enhanced the phosphorylation of AMP-activated protein kinase in the ischemia/reperfusion-injured heart. In cultured cardiac myocytes, FSTL1 suppressed apoptosis in response to hypoxia/reoxygenation and lipopolysaccharide-stimulated expression of proinflammatory genes through its ability to activate AMP-activated protein kinase. Ischemia/reperfusion led to enhancement of bone morphogenetic protein-4 expression and Smad1/5/8 phosphorylation in the heart, and FSTL1 suppressed the increased phosphorylation of Smad1/5/8 in ischemic myocardium. Treating cardiac myocytes with FSTL1 abolished the bone morphogenetic protein-4-stimulated increase in apoptosis, Smad1/5/8 phosphorylation, and proinflammatory gene expression. In cultured macrophages, FSTL1 diminished lipopolysaccharide-stimulated expression of proinflammatory genes via activation of AMP-activated protein kinase and abolished bone morphogenetic protein-4-dependent induction of proinflammatory mediators. CONCLUSIONS: Our data indicate that FSTL1 can prevent myocardial ischemia/reperfusion injury by inhibiting apoptosis and inflammatory response through modulation of AMP-activated protein kinase- and bone morphogenetic protein-4-dependent mechanisms, suggesting that FSTL1 could represent a novel therapeutic target for post-myocardial infarction, acute coronary syndrome.
Authors: Enrique Lara-Pezzi; Leanne E Felkin; Emma J Birks; Padmini Sarathchandra; Kalyani D Panse; Robert George; Jennifer L Hall; Magdi H Yacoub; Nadia Rosenthal; Paul J R Barton Journal: Endocrinology Date: 2008-07-10 Impact factor: 4.736
Authors: Masayuki Shimano; Noriyuki Ouchi; Kazuto Nakamura; Bram van Wijk; Koji Ohashi; Yasuhide Asaumi; Akiko Higuchi; David R Pimentel; Flora Sam; Toyoaki Murohara; Maurice J B van den Hoff; Kenneth Walsh Journal: Proc Natl Acad Sci U S A Date: 2011-10-10 Impact factor: 11.205
Authors: Christian Widera; Rüdiger Horn-Wichmann; Tibor Kempf; Kerstin Bethmann; Beate Fiedler; Sarita Sharma; Ralf Lichtinghagen; Holger Leitolf; Boris Ivandic; Hugo A Katus; Evangelos Giannitsis; Kai C Wollert Journal: Clin Chem Date: 2009-07-02 Impact factor: 8.327
Authors: Archana Tadimalla; Peter J Belmont; Donna J Thuerauf; Matthew S Glassy; Joshua J Martindale; Natalie Gude; Mark A Sussman; Christopher C Glembotski Journal: Circ Res Date: 2008-10-16 Impact factor: 17.367
Authors: Mitsuru Seki; Jeffery C Powers; Sonomi Maruyama; Maria A Zuriaga; Chia-Ling Wu; Clara Kurishima; Lydia Kim; Jesse Johnson; Anthony Poidomani; Tao Wang; Eric Muñoz; Sudarsan Rajan; Joon Y Park; Kenneth Walsh; Fabio A Recchia Journal: Circ Heart Fail Date: 2018-01 Impact factor: 8.790
Authors: Frank M Bengel; Richard T George; Karl H Schuleri; Albert C Lardo; Kai C Wollert Journal: Eur Heart J Cardiovasc Imaging Date: 2013-05-29 Impact factor: 6.875
Authors: Brian T Campfield; Christi L Nolder; Anthony Marinov; Daniel Bushnell; Amy Davis; Caressa Spychala; Raphael Hirsch; Andrew J Nowalk Journal: Microb Pathog Date: 2014-04-24 Impact factor: 3.738
Authors: Peter P Rainer; Scarlett Hao; Davy Vanhoutte; Dong Ik Lee; Norimichi Koitabashi; Jeffery D Molkentin; David A Kass Journal: Circ Res Date: 2014-02-26 Impact factor: 17.367